Is There a Role for Immunotherapy in Patients with KRAS G12C

Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Related Keywords

Luis Raez , , Biomarker Testing , Targeted Therapies , Non Small Cell Lung Cancer , Nsclc , Stk11 , Keap1 , Tp53 , Skras , Immunotherapies ,